CR6640A - Nuevos derivados de tiazolidindiona como agentes antidiabeticos - Google Patents

Nuevos derivados de tiazolidindiona como agentes antidiabeticos

Info

Publication number
CR6640A
CR6640A CR6640A CR6640A CR6640A CR 6640 A CR6640 A CR 6640A CR 6640 A CR6640 A CR 6640A CR 6640 A CR6640 A CR 6640A CR 6640 A CR6640 A CR 6640A
Authority
CR
Costa Rica
Prior art keywords
antidiabetic agents
tiazolidindiona
new derivatives
refers
agents
Prior art date
Application number
CR6640A
Other languages
English (en)
Inventor
Carlos Del Castillo Nieto Juan
De Ramon Amat Elisabet
Mourelle Manzini Marisabel
Original Assignee
Vita Invest Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vita Invest Sa filed Critical Vita Invest Sa
Publication of CR6640A publication Critical patent/CR6640A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

se refiere a compuestos de formula general (I) a sus posibles sales farmaceuticamente aceptables y formas tautomeras. Tambien se refiere a un procedimiento para su obtencion y a su uso como antidiabeticos E hipolipemiantes, solos o en combinacion con otros agentes antidiabeticos como la sulfonilureas o biguanidas, asi como para el tratamiento de complicaciones asociadas a la resistencia a la insulina, tales como hipertension hiperuricemia u otros trastornos cardiovasculares, metabolicos, endocrinos u otros relacionados con la diabetes
CR6640A 1999-11-18 2002-05-15 Nuevos derivados de tiazolidindiona como agentes antidiabeticos CR6640A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009902533A ES2156574B1 (es) 1999-11-18 1999-11-18 Nuevos derivados de tiazolidindiona como agentes antidiabeticos

Publications (1)

Publication Number Publication Date
CR6640A true CR6640A (es) 2004-03-05

Family

ID=8310628

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6640A CR6640A (es) 1999-11-18 2002-05-15 Nuevos derivados de tiazolidindiona como agentes antidiabeticos

Country Status (37)

Country Link
US (1) US7001910B1 (es)
EP (1) EP1231211B1 (es)
JP (1) JP2003514817A (es)
KR (1) KR100518110B1 (es)
CN (1) CN1159314C (es)
AP (1) AP1330A (es)
AR (1) AR031080A1 (es)
AT (1) ATE241622T1 (es)
AU (1) AU770045B2 (es)
BG (1) BG106699A (es)
BR (1) BR0015613A (es)
CA (1) CA2391913A1 (es)
CO (1) CO5261560A1 (es)
CR (1) CR6640A (es)
CZ (1) CZ20021654A3 (es)
DE (1) DE60003072T2 (es)
DK (1) DK1231211T3 (es)
EA (1) EA004301B1 (es)
EE (1) EE200200254A (es)
ES (2) ES2156574B1 (es)
GE (1) GEP20043240B (es)
HR (1) HRP20020426A2 (es)
HU (1) HUP0203478A2 (es)
IL (1) IL149634A0 (es)
IS (1) IS2014B (es)
MA (1) MA26844A1 (es)
MX (1) MXPA02005011A (es)
NO (2) NO20022336L (es)
NZ (1) NZ519264A (es)
OA (1) OA12089A (es)
PE (1) PE20010858A1 (es)
PL (1) PL354877A1 (es)
PT (1) PT1231211E (es)
SK (1) SK6752002A3 (es)
WO (1) WO2001036416A1 (es)
YU (1) YU40202A (es)
ZA (1) ZA200203906B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174748B1 (es) * 2001-01-31 2003-09-16 Vita Lab Nueva sal de tiazolidindiona y sus polimorfos como agentes antidiabeticos y procedimiento para la obtencion de los mismos.
KR100450700B1 (ko) * 2002-03-22 2004-10-01 주식회사종근당 티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
US7713983B2 (en) 2003-03-03 2010-05-11 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
CL2004000409A1 (es) 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
US20050014732A1 (en) * 2003-03-14 2005-01-20 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-diabetic agent
US8283354B2 (en) 2004-09-02 2012-10-09 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US7928107B2 (en) 2004-09-02 2011-04-19 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
CZ297347B6 (cs) * 2004-09-21 2006-11-15 Zentiva, A. S. Zpusob prípravy rosiglitazonu
JP5546372B2 (ja) * 2010-06-30 2014-07-09 積水メディカル株式会社 ベンジルヒダントイン化合物の製造法
WO2016184895A1 (en) 2015-05-18 2016-11-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Means for detecting or measuring a biological activity of a botulinum toxin
US10689374B1 (en) 2019-07-12 2020-06-23 United Arab Emirates University Pyrimidine-thiazolidinone derivatives
US10702525B1 (en) 2019-09-04 2020-07-07 United Arab Emirates University Pyrimidine derivatives as anti-diabetic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
IL149634A0 (en) 2002-11-10
GEP20043240B (en) 2004-05-25
DE60003072D1 (de) 2003-07-03
HRP20020426A2 (en) 2004-02-29
AU1281501A (en) 2001-05-30
BG106699A (bg) 2003-02-28
EE200200254A (et) 2003-06-16
NO20022336L (no) 2002-07-09
CN1402724A (zh) 2003-03-12
NO20022379D0 (no) 2002-05-16
MA26844A1 (fr) 2004-12-20
HUP0203478A2 (hu) 2003-02-28
OA12089A (en) 2006-05-04
US7001910B1 (en) 2006-02-21
BR0015613A (pt) 2002-07-23
EP1231211A1 (en) 2002-08-14
NZ519264A (en) 2003-10-31
ES2199878T3 (es) 2004-03-01
AP1330A (en) 2004-11-25
DK1231211T3 (da) 2003-10-27
DE60003072T2 (de) 2004-04-01
IS6386A (is) 2002-05-15
PT1231211E (pt) 2003-09-30
PE20010858A1 (es) 2001-08-22
JP2003514817A (ja) 2003-04-22
CN1159314C (zh) 2004-07-28
ATE241622T1 (de) 2003-06-15
EP1231211B1 (en) 2003-05-28
ZA200203906B (en) 2004-03-26
IS2014B (is) 2005-06-15
CZ20021654A3 (cs) 2002-09-11
WO2001036416A1 (es) 2001-05-25
NO20022336D0 (no) 2002-05-15
EA200200470A1 (ru) 2002-10-31
YU40202A (sh) 2006-01-16
ES2156574A1 (es) 2001-06-16
ES2156574B1 (es) 2002-02-01
CA2391913A1 (en) 2001-05-25
AP2002002512A0 (en) 2002-06-30
AR031080A1 (es) 2003-09-10
MXPA02005011A (es) 2003-10-14
EA004301B1 (ru) 2004-02-26
KR20020079737A (ko) 2002-10-19
CO5261560A1 (es) 2003-03-31
PL354877A1 (en) 2004-03-08
SK6752002A3 (en) 2002-09-10
AU770045B2 (en) 2004-02-12
KR100518110B1 (ko) 2005-10-04

Similar Documents

Publication Publication Date Title
CR6640A (es) Nuevos derivados de tiazolidindiona como agentes antidiabeticos
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
CL2010000375A1 (es) Compuestos mimeticos de glucocorticoides derivados de hidroxialquilo sustituidos por heterociclos; procedimiento de preparacion; composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de un estado o trastorno seleccionado de diabetes tipo ii, obesidad, hipertension, entre otras (divisional de solicitud 585-03).
UA86997C2 (ru) Производные антраниламида, пестицидная композиция на их основе и промежуточные соединения
CA2266401A1 (en) Use of sibutramine analogues to prevent the development of diabetes
ECSP055860A (es) Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
RS93604A (en) Substituted phenylacetamides and their use as glucokinase activators
NZ593050A (en) Glucagon-like-peptide-2 (glp-2) analogues
BRPI0607762B8 (pt) análogos de glp-1, composição farmacêutica contendo os mesmos e uso de um composto
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
EP1661961A3 (en) Metal polishing composition and method of polishing using the same
WO2000058293A3 (en) Glucokinase activators
BR0112519A (pt) Derivados anticonvulsivantes úteis para prevenir o desenvolvimento de diabetes melito do tipo ii e sìndrome x
AR052404A1 (es) Hidratos y polimorfos de 4-(((7r)-8-ciclopentil-7-etil-5,6,7,8-tetrahidro-5-metil-6-oxo-2-pteridinil)amino)-3- metoxi-n-(1-metil-4-piperidinil)-benzamida, procedimiento para su preparacion y su uso como farmaco
MY134664A (en) 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipedemia
PA8562801A1 (es) Nuevos derivados de pirido (2,1-a) isoquinolina
CA2474578A1 (en) Novel pyridin- and pyrimidin-derivatives
WO2003033524A3 (en) Peptidyl ketones as inhibitors of dpiv
GEP20074144B (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
UY27244A1 (es) Uso del acido- (4´-trifluormetilfenil) - amida (z) -2- ciano-3- hidroxi-but-2-enoico para el tratamiento de la esclerosis multiple
ATE267601T1 (de) Pharmazeutische zusammensetzung enthaltend pemetrexed zusammen mit monothioglycerol, l- cystein oder thioglykolsäure
CL2004000391A1 (es) Compuestos derivados de 1,3-oxazol; composicion farmaceutica; y uso de los compuestos para tratar trastornos metabolicos, tales como diabetes, dislipidemia, resistencia a la insulina.
IL158155A0 (en) Use of erythropoietin to ameliorate chemotherapy-induced toxicity in vivo
ATE333901T1 (de) Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin
TW200420531A (en) Use of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)